Nuwellis, Inc. Financial Results Announcement for Q1 2025
MINNEAPOLIS, April 22, 2025 – Nuwellis, Inc. (Nasdaq: NUWE), a pioneering medical technology company dedicated to enhancing the lives of individuals experiencing fluid overload, has officially announced its plans to release its financial results for the first quarter of 2025 on May 13, 2025. This results announcement will be accompanied by a conference call and webcast scheduled for 9:00 AM ET, where the company will provide an overview of its financial achievements as well as an update on its business strategies.
The live webcast will be accessible on the Investors page of the Nuwellis website. Those interested can also participate in the conference call by calling 1-800-579-2543 for U.S. participants, or +1-785-424-1789 for international callers. To ensure smoother communication, callers will need to use the conference ID: NUWEQ1. Afterward, an audio archive of the financial discussion will be accessible on the same webpage to keep investors up to date.
Overview of Nuwellis, Inc.
Nuwellis, Inc. (Nasdaq: NUWE) is committed to revolutionizing the treatment of patients dealing with fluid overload through innovative medical technology. The company primarily aims to enhance patient care via the commercialization of the Aquadex SmartFlow system, a sophisticated solution designed for ultrafiltration therapy. With its headquarters in Minneapolis and a subsidiary located in Ireland, Nuwellis is on a vital mission to provide safe, effective treatment options for patients struggling with fluid overload conditions.
Understanding the Aquadex SmartFlow® System
The Aquadex SmartFlow system is a cutting-edge therapy that has shown clinical effectiveness in managing patients with hypervolemia or fluid overload. This system employs a straightforward, adaptable, and intelligent method to help patients remove excess fluid. It is designated for temporary treatments lasting up to 8 hours, or extended use exceeding 8 hours, specifically designed for adult and pediatric patients weighing 20 kg or more, who do not respond to traditional medical treatments, including diuretics. Importantly, all treatments must be administered by trained healthcare professionals in clinical environments, ensuring a high standard of care.
Connect with Nuwellis, Inc.
If you are an investor and have any inquiries, do not hesitate to contact Louisa Smith at Gilmartin Group LLC via email at ir@nuwellis.com. They are ready to assist with any questions you may have about this upcoming financial report or about the company in general.
Frequently Asked Questions
What is the date for Nuwellis, Inc.'s financial report release?
Nuwellis, Inc. is set to release its financial results for the first quarter of 2025 on May 13, 2025.
Where can I access the live conference call?
The live conference call can be accessed by calling 1-800-579-2543 (U.S.) or 1-785-424-1789 (international) using the conference ID: NUWEQ1.
What is the Aquadex SmartFlow system?
The Aquadex SmartFlow system is designed to treat fluid overload in patients, delivering ultrafiltration therapy that can be adjusted based on the individual needs of patients.
Who should use the Aquadex SmartFlow system?
The system is indicated for adult and pediatric patients over 20 kg whose fluid overload is not responsive to diuretics and must be administered by trained healthcare providers.
How can I find more information about Nuwellis?
For more information about Nuwellis, you can visit their Investors page at ir.nuwellis.com or follow them on their social media platforms.
